Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products that address therapeutic needs in the field of neuroscience. The Company began a Phase II study of TO-2061, a low dose of ondansetron adjunctive treatment for patients with obsessive compulsive disorder (OCD), who has not adequately responded to first-line therapy. Intermezzo is formulated as a sublingual tablet containing a bicarbonate-carbonate buffer and is absorbed in both women and men. Intermezzo was studied in two Phase III clinical trials involving more than 370 patients. Ambien and its generic equivalents are available in doses of 5 milligram and 10 milligram. Ambien CR and its generic equivalents are available in doses of 6.25 milligram and 12.5 milligram. It has a primary manufacturing and supply agreement with Patheon, Inc. Patheon to manufacture a supply of Intermezzo for use outside the United States.